Table 6. The clinicopathological characteristics of the female MPLC patients.
| 19del | 19del + L858R | 19del + rare mutation | 19del + WT | L858R + rare mutation | L858R | L858R + WT | G719X | 20ins + WT | WT | |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | ||||||||||
| <30 | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 8.33% | 0.00% | 0.00% | 0.00% |
| <40 | 0.00% | 0.00% | 33.33% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.53% |
| <50 | 0.00% | 0.00% | 33.33% | 9.09% | 0.00% | 0.00% | 16.67% | 0.00% | 0.00% | 31.58% |
| <60 | 50.00% | 25.00% | 0.00% | 36.36% | 50.00% | 23.08% | 25.00% | 100.00% | 100.00% | 42.11% |
| <70 | 50.00% | 50.00% | 0.00% | 45.45% | 33.33% | 53.85% | 41.67% | 0.00% | 0.00% | 15.79% |
| <80 | 0.00% | 25.00% | 33.33% | 9.09% | 16.67% | 23.08% | 8.33% | 0.00% | 0.00% | 0.00% |
| Site | ||||||||||
| Left | 33.33% | 15.79% | 50.00% | 43.48% | 43.75% | 38.46% | 42.31% | 0.00% | 0.00% | 48.72% |
| Right | 66.67% | 84.21% | 50.00% | 56.52% | 56.25% | 61.54% | 57.69% | 100.00% | 100.00% | 51.28% |
| Pathology | ||||||||||
| Adenocarcinoma | 100.00% | 100.00% | 83.33% | 78.26% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 89.74% |
| Squamous carcinoma | 0.00% | 0.00% | 16.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Atypical hyperplasia of adenoma | 0.00% | 0.00% | 0.00% | 21.74% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 10.26% |
| TNM stage | ||||||||||
| Tis | 0.00% | 0.00% | 0.00% | 9.09% | 0.00% | 7.69% | 0.00% | 0.00% | 0.00% | 15.79% |
| Ia | 66.67% | 75.00% | 66.67% | 54.55% | 83.33% | 23.08% | 91.67% | 100.00% | 100.00% | 68.42% |
| Ib | 33.33% | 25.00% | 33.33% | 27.27% | 0.00% | 46.15% | 8.33% | 0.00% | 0.00% | 15.79% |
| Ia + Ib | 0.00% | 0.00% | 0.00% | 9.09% | 16.67% | 23.08% | 0.00% | 0.00% | 0.00% | 0.00% |